DiscoveryProbe™ Metabolism-related Compounds Panel

Compound Panel Contents

Catalog No.	Product Name	Summary	Targets	CAS Number	Smiles
A5143	Finasteride	Inhibitor of Type II 5α-reductase	Metabolism|5-alpha Reductase	98319-26-7	CC12CCC3C(C1CCC2C(=O)NC(C)(C)C)CCC4C3(C=CC(=O)N4)C
A4336	Mycophenolate Mofetil	IMPDH inhibitor	Metabolism|Dehydrogenase	128794-94-5	CC1=C(C(=C(C2=C1COC2=O)O)CC=C(C)CCC(=O)OCCN3CCOCC3)OC
A4365	Lovastatin	HMG-CoA reductase inhibitor	Metabolism|HMG-CoA Reductase	75330-75-5	CCC(C)C(=O)OC1CC(C=C2C1C(C(C=C2)C)CCC3CC(CC(=O)O3)O)C
B7794	BMS 309403	FABP4 inhibitor,potent and selective	Metabolism|Lipid Metabolism	300657-03-8	OC(COC1=CC(C2=CC=CC=C2N3N=C(C4=CC=CC=C4)C(C5=CC=CC=C5)=C3CC)=CC=C1)=O
A4325	PF-2545920	PDE10A inhibitor,potent and selective	Metabolism|PDE	1292799-56-4	CN1C=C(C(=N1)C2=CC=C(C=C2)OCC3=NC4=CC=CC=C4C=C3)C5=CC=NC=C5
A4331	GSK256066	PDE4-inhibitor,selective and highly potent	Metabolism|PDE	801312-28-7	CC1=C2C(=CC(=C1)S(=O)(=O)C3=CC=CC(=C3)C(=O)N(C)C)C(=C(C=N2)C(=O)N)NC4=CC(=CC=C4)OC
Download the Metabolism-related Compounds Panel - XLSX       Download the Metabolism-related Compounds Panel - SDF

Advantages

• Available in stock with overnight delivery and free shipping over $500
• Cost-effective and competitive price to save your findings
• Potent, selective and cell-permeable in inhibiting or activating target molecules
• Diverse in chemical structure and route of administration (oral/i.m/i.v injection etc.)
• Detailed files describing potency, selectivity and applications etc.
• Supported by published data from top peer-reviewed journals
• Guaranteed high quality with NMR and HPLC validation

产品描述
A wide range of well-characterized bioactive molecules that covers various targets related to metabolism, including PPAR, HMG-CoA reductase, HSP, PDE and DHFR etc. Facilitate your research towards the insights of diabetes, hypertension ad hormone regulation etc. Applicable in cellular assays, animal models and drug screenings etc.
References
1. Ahmadian M, Suh JM, Hah N, Liddle C, Atkins AR, Downes M, Evans RM. PPARγ signaling and metabolism: the good, the bad and the future. Nat Med. 2013 May;19(5):557-66. 
Abstract 
Thiazolidinediones (TZDs) are potent insulin sensitizers that act through the nuclear receptor peroxisome proliferator-activated receptor-γ (PPARγ) and are highly effective oral medications for type 2 diabetes. Recent studies that have supported the continuing physiologic and therapeutic relevance of the PPARγ pathway also provide opportunities to develop newer classes of molecules that reduce or eliminate adverse effects. This review highlights key advances in understanding PPARγ signaling in energy homeostasis and metabolic disease and also provides new explanations for adverse events linked to TZD-based therapy.